Zealand begins Phase III of dasiglucagon in severe hypoglycemia

Zealand Pharma A/S (CSE:ZEAL) began a double-blind, international Phase III trial comparing repeated doses of 0.6 mg subcutaneous dasiglucagon in a rescue pen to GlucaGen for 15 weeks in 90 Type I diabetics with severe hypoglycemia. The trial is evaluating immunogenicity and safety...